Prosecution Insights
Last updated: November 13, 2026
Application No. 18/275,875

COMPOSITION FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE

Non-Final OA §101§102§103
Filed
Aug 04, 2023
Priority
Feb 05, 2021 — RE 10-2021-0016870 +1 more
Examiner
LEONARD, ARTHUR S
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ki Taek Nam
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
264 granted / 523 resolved
-9.5% vs TC avg
Strong +50% interview lift
Without
With
+50.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
56 currently pending
Career history
598
Total Applications
across all art units

Office Action

§101 §102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claim status Claims 1-30 are pending Claims 7-30 are withdrawn Claims 1-6 are under examination Election/Restrictions Applicant’s election of the following invention without traverse in the reply filed on 2/06/2026 is acknowledged. The requirement is still deemed proper and is therefore made FINAL. Group I, claims 1-3, drawn to a composition comprising a stem cell. Claims 7-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable linking claim. Rejoinder The restriction requirement between Groups I-II, as set forth in the Office action mailed on 12/09/2025, has been reconsidered in view of the prior art. The restriction requirement between Groups I-II is hereby withdrawn. Claims 4-6, directed to previously non-elected Group II are no longer withdrawn from consideration. In view of the above noted withdrawal of the restriction requirement, applicant is advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Information Disclosure Statement The information disclosure statement (IDS) submitted on 12/13/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. However, Applicant is reminded that the listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Objections to the Specification First, the disclosure is objected to because of the following informalities: Paragraphs [00171] and [00172] in reference to Figures 27 and 28, respectively, describe elements in the figures with colors (e.g., red). However, Applicant has not submitted drawings executed in color. Furthermore, Applicant is reminded that color photographs and color drawings are not accepted in utility applications unless a petition filed under 37 CFR 1.84(a)(2) is granted. Any such petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification: The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2). Second, the disclosure is objected to because of the following informalities: Table 1, p. 47, indicated that SEQ ID NOs:15 & 16 correspond to “Hoxb1”, which is a typographical error, as these SEQ ID NOs appear to correspond to “Hoxb7”. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-3 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a natural product without significantly more. The claim(s) recite(s) a kidney derived stem cell which is not markedly different from its naturally occurring counterpart. This judicial exception is not integrated into a practical application because the natural product is not linked to a particular technology. The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the additional limitations are well-understood, routine and conventional in cell biology. Briefly summarized here, the subject eligibility guidance cites a two part test: is the claimed invention directed to a statutory class of invention (Step 1), if so then is the claimed invention as a whole directed to a law of nature, natural phenomena, or an abstract idea (i.e. set forth or described in the claim) (Step 2A, prong one), if so then is the claimed invention recite additional elements that integrate the judicial exception into a practical application (Step 2A, prong two), if not then does the claim as a whole amount to significantly more than the judicial exception (Step 2B). In regard to Step 1, Claims 1-3 are drawn to a composition of matter-a cell. In regard to Step 2A prong one, Claims 1-3 are drawn to a nature-based product which is not markedly different from its naturally occurring counterpart. Specifically, independent claims 1-3 are directed to a pharmaceutical composition of kidney-tissue derived stem cells expressing a Lrig1 protein or gene, as well as a Klf6 protein or gene. These claims all encompass naturally occurring stem cells in a developing kidney. This option of the claims is a naturally occurring product. Because instant claims are directed to a nature-based product, i.e., kidney stem cells, the nature-based product is analyzed to determine whether it has markedly different characteristics from any naturally occurring counterpart(s) in their natural state. Applicant is directed to the post-filing publication of the inventor Yura Lee et al., (JASN, 2024, 35:1702-1714), which evidences that Lrig1+ cells are present in kidney tissue during development (Results, p.1704, last para., p. 1705, 1st and 3rd para., see also Fig. 1-2), and that both Lrig1+ and Klf6+ cells are present in the adult kidney’s stem cell niche (p. 1710, 3rd-5th para.). Thus, instant claims encompass kidney tissue derived stem cells that are identical (no difference in structural or functional characteristics) to naturally occurring kidney stem cells. Furthermore, the fact that instant claim recites “for preventing or treating kidney disease…as an active ingredient” does not differentiate it from the naturally occurring kidney cells because although the claimed cells may have an intended use, they are identical to what exists in nature (i.e., same Lrig1+ cell type). In regard to the pharmaceutical composition features of instant claims, there is no indication in the specification that placing the cells in a pharmaceutical composition results in the cells having any characteristics (structural, functional, or otherwise) that are different from the naturally occurring cells in their natural state. Because there is no difference between the claimed and naturally occurring cells, the claimed cells do not have markedly different characteristics, and thus are a “product of nature” exception. Accordingly, instant claims are directed to a judicial exception. In regard to Step 2A prong two, the judicial exception is not integrated into a practical application. In particular, although Claim 1 recites the intended use of the composition of cells, no additional elements to integrate the claimed cell into a practical application are claimed. Moreover, Claim 1 recites a single additional element- that the cell is in a pharmaceutical composition. The term pharmaceutic composition is extremely broad and encompasses many types of sterile physiological solutions, including culturing buffers. Thus, merely placing the natural product into a generic buffer so that the cell may survive and be cultured does not add a meaningful limitation as it is a nominal extra-solution component of the claim as is a necessary precursor for all of the uses of the cell, and is nothing more than an attempt to generally link the cell product to a particular biotechnology. Clearly, combining the natural cell in a pharmaceutical composition on its own does nothing to improve a technology, effect a particular treatment, or implement with a particular device to provide a meaningful limitation on the judicial exception. In regard to Step 2B, the claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. As stated supra, Claims 1-3 recite no additional elements to the cell beyond the intended uses. In regard to Claim 1, which recites a single additional element as a pharmaceutical composition, as discussed above with respect to the integration of the natural product into a practical application, the additional element of combining a pharmaceutical composition amounts to no more than a sterile physiological buffer to keep the cells alive, and do not provide an inventive concept. Therefore, Claims 1-3 are directed to a natural cell product, that is not markedly different from its natural counterpart, is not integrate a practical application, and does not include elements that amount to significantly more than the natural product itself and do not qualify as patent eligible subject matter under 35 U.S.C. § 101. Claim Rejections - 35 USC § 102/103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-6 are rejected under 35 U.S.C. 102(a)(2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Nishinakamura et al. (US2022/0135940, filed 11/08/2018, published 5/05/2022), as evidenced by Jones (US2010/0190201, filed 7/11/2008) and Bialkowska et al., (Development, 2017, 144:737-754) With respect to the structure of the stem cells and organoids of claims 1 and 4, Nishinakamura teaches an kidney-tissue derived mouse embryonic stem cells cultured with Wnt agonists to form a kidney-spheroid. Note that in regard to Applicant’s special definition of organoid referring to a 3D “tissue-like model produced through an artificial culture process without being collected or obtained from an animal” [0046], the Examiner is considering the cultured stem cell derived spheroids of Nishinakamura as not being collected or obtained from an animal. In other words, although the parental stem cells were collect from an animal, the resulting 3D spheroid was not. With respect to the intended uses of the stem cells and organoids of claims 1 and 4-5, although Nishinakamura does teach that the generated structures can be transplanted into immunodeficient mice (Example 9, [0323]), they are silent to the use of said invention to prevent or treat kidney diseases, which is an intended use of the claimed composition. It is noted that the use of a product for a particular purpose is not afforded patentable weight in a product claim where the body of the claim does not depend on the preamble for completeness but, instead, the structural limitations are able to stand alone. The MPEP states that,”.. in apparatus, article, and composition claims, intended use must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art.” In re Casey, 152 USPQ 235 (CCPA 1967); In re Otto , 136 USPQ 458, 459 (CCPA 1963)(MPEP 2111.02). In instant case, the kidney tissue-derived stem cells and spheroids thereof appear to be capable of transplantation into a subject and in the broadest of terms capable of treating a kidney disease. Furthermore, the claimed element of a pharmaceutical composition has no specifical definition in Applicant’s specification, and amounts to no more than a sterile physiological buffer to keep the cells/spheroid alive. With respect to the LRIG1 marker expression of the stem cells and organoids of claims 1 and 4, Nishinkakamura teaches the kidney-tissue derived stem cells in spheroid from express anterior intermediate mesoderm markers OSR1, PAX2, PAX8, EMX2, LHX1, and GATA3 (Example 4, [0297], see Fig. 2). Furthermore, as the anterior intermediate mesoderm differentiates into more committed Wolffian Duct (WD) progenitors, the kidney-spheroid tissue differentially expresses stem cell markers OSR1, SIX2, and GATA3, but not WT1 or RET (Example 5, [0302], see Fig. 15). [AltContent: textbox ([img-media_image1.png])]Although Nishinakamura is silent to the expression of LRIG1, MPEP 2112.01(II) recites that "products of identical chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable." Furthermore, there is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the time of filing of the invention, but only that the subject matter is in fact inherent in the prior art reference. Notably, Fig. 12 of Applicant’s drawings (adjacent) demonstrates RT-PCR levels of kidney stem cell genes expressed in kidney organoids [00157, 0213] of specification), which overlap with the expression profile of the kidney spheroids of Nishinakamura. Moreover, Jones et al (US2010) evidences that well-before the time of filing, LRIG1 was a known stem cell marker, and that its expression levels changed over time in developing stem cell “clusters” as stem cells transitioned to cycling epithelial progenitor cells ([0005], p. 3, Cell Markers, Table). Since the Patent Office does not have the facilities for examining and comparing Applicants' organoids with the spheroids of Nishinakamura, the burden is upon Applicants to show a distinction between the material structural and functional characteristics of the claimed organoids and the spheroids of the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594. In regard to claims 2 and 5, although Nishinakamura is silent to the expression of KLF6, as stated supra, the expression of this marker appears to be an inherent feature of the developing kidney tissue. Furthermore, Bialkowska et al. (2017) evidences that well-before the time of filing, KLF6 was a known progenitor cell marker that is expressed in the developing kidney, as well as in certain kidney disease wherein it is upregulated during podocyte stress (p. 740, Table 1, p. 748, 3rd para., see Fig 5). In regard to claims 3 and 6, as stated supra, the pharmaceutical composition is extremely broad and reasonably encompasses generic buffers or sterile media, while the intended use of treating a certain kidney disease does not change the structure or function of the taught kidney-tissue derived stem cells and spheroid. Accordingly, Nishinakamura, as evidenced by Jones and Bialkowska, anticipate or, in the alternative, make obvious instant claims. Conclusion No claims are allowed. Examiner Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to ARTHUR S LEONARD whose telephone number is (571)270-3073. The examiner can normally be reached on Mon-Fri 9am-5pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Doug Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ARTHUR S LEONARD/Examiner, Art Unit 1631
Read full office action

Prosecution Timeline

Aug 04, 2023
Application Filed
May 05, 2026
Non-Final Rejection mailed — §101, §102, §103
Sep 03, 2026
Response Filed
Sep 03, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788829
COMPOSITIONS USEFUL FOR TREATING GM1 GANGLIOSIDOSIS
4y 3m to grant Granted Nov 10, 2026
Patent 12766097
TREATMENT OF CNS LYMPHOMA AND SYSTEMIC LYMPHOMA WITH INTRACEREBROVENTRICULARLY ADMINISTERED CD19 CAR
6y 5m to grant Granted Oct 20, 2026
Patent 12760085
ENHANCED T-CELL RECEPTOR STAR AND APPLICATION THEREOF
3y 6m to grant Granted Oct 13, 2026
Patent 12760274
COMPOSITIONS AND METHODS OF STIMULATING AND EXPANDING T CELLS
4y 1m to grant Granted Oct 13, 2026
Patent 12734250
MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME
3y 8m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+50.4%)
Low
PTA Risk
Based on 523 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month